Final remarks and presentation of awards.
Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis
Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies
Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Management and Prevention of AEs Associated With Ponatinib Improved
Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL
Pirobrutinib sustained BTK inhibition and improved progression-free survival in patients with CLL and SLL, data from the phase 3 BRUIN CLL-321 trial showed.
